About Headsafe

Headsafe was established in Sydney, Australia in 2017 by Dr. Adrian Cohen to develop and commercialize the patented NUROCHEK™ system*. Headsafe’s present focus lies in scientific and clinical research into the NUROCHEK system and its application in the assessment of brain function, with research partnerships in the United States, Australia, New Zealand, and the United Kingdom.

*FDA cleared for sale in the United States: the Nurochek-II System is intended for prescription use in healthcare facilities for subjects aged between 16 and 46 years old, for the aid in diagnosis of mild traumatic brain injury (mTBI) in conjunction with a standard neurological assessment.

Not yet available EU or ANZ